Dr. Kastan studies the mechanisms of cancer cell growth and survival, particularly in brain tumors and blood cancers. For instance, he investigates how mutations in genes, such as those in glioblastoma cells, allow tumors to grow aggressively despite treatment efforts. He also examines how a protein called p53, which typically helps control cell growth and death, behaves under different conditions, such as low oxygen levels. Furthermore, he explores the sensitivity of specific blood cells to chemotherapy, aiming to develop strategies that could improve treatment outcomes for patients with leukemia and other cancers.
Key findings
In his study on SKMG-3 glioma cells, Dr. Kastan found that these cells have extra copies of the EGFR gene, which contributes to aggressive brain tumor growth.
His research showed that low oxygen levels increase p53 protein levels but do not cause cell death as expected, which may change how we approach cancer therapies.
Dr. Kastan discovered that CD34+ hematopoietic progenitors become up to five times more sensitive to the chemotherapy drug BCNU when treated with O6-benzylguanine, indicating potential for lower drug doses.
The study of the genes WAF1/CIP1 and GADD45 revealed that both are more effective at stopping cell growth when working together in the presence of p53, enhancing our understanding of cancer response to DNA damage.
Using two-color flow cytometry, he achieved a remarkable sensitivity of 0.03% for detecting minimal residual leukemia, allowing for better monitoring post-treatment.
Frequently asked questions
Does Dr. Kastan study brain cancer?
Yes, he focuses on the mechanisms behind brain tumors, particularly glioblastoma.
What cancer treatments has Dr. Kastan researched?
He has researched how specific gene mutations affect tumor growth and how particular blood cells respond to chemotherapy.
Is Dr. Kastan's work relevant for leukemia patients?
Absolutely, his studies on detecting minimal residual leukemia and improving chemotherapy sensitivity are particularly beneficial for these patients.
How does Dr. Kastan's research help cancer treatments?
By understanding the genetic and cellular behaviors in cancer, his work aims to improve treatment effectiveness and potentially allow for lower drug doses.
What is the significance of the p53 protein in cancer?
The p53 protein helps control cell growth and survival; understanding its function can lead to better strategies for blocking cancer cell survival.
Publications in plain English
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
2001
Molecular and cellular biology
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W +6 more
Plain English This study looked at how low oxygen levels (hypoxia) affect a protein called p53, which helps control cell behavior, especially during stress. Researchers found that while hypoxia increases the amount of p53 in cells, it does not trigger the usual reactions that lead to cell death, unlike damage to DNA, which activates both cell repair and death processes. This matters because understanding how p53 works differently under various stresses can help improve cancer treatments, as p53 often plays a role in stopping cancer cells from surviving.
Who this helps: Patients with cancer.
Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
2001
Acta neuropathologica
Thomas C, Ely G, James CD, Jenkins R, Kastan M +3 more
Plain English The study looked at a specific glioblastoma cell line called SKMG-3, which has unique gene mutations that help it grow aggressively. They found that SKMG-3 cells have extra copies of the EGFR gene and other mutations that disrupt normal tumor suppression, leading to high levels of the EGFR protein and allowing the cells to grow despite treatment. This discovery is important because it helps understand how these genetic changes contribute to the growth of brain tumors and could guide future treatments.
Who this helps: This research helps doctors and researchers working on brain cancer treatments.
Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
1996
Blood
Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C
Plain English This study looked at a specific type of blood cell, called CD34+ hematopoietic progenitors, found in human bone marrow. Researchers discovered that these cells have low levels of a protein that helps repair DNA, making them more vulnerable to certain cancer treatments (nitrosoureas). When treated with O6-benzylguanine, these cells became up to five times more sensitive to a chemotherapy drug called BCNU, which could mean lower doses of the drug are needed to be effective.
Who this helps: This research benefits patients undergoing chemotherapy, particularly those with blood cancers.
Similarity of the DNA-damage responsiveness and growth-suppressive properties of waf1/cip1 and gadd45.
1995
International journal of oncology
Zhan Q, Eldeiry W, Bae I, Alamo I, Kastan M +2 more
Plain English This study looked at how two genes, WAF1/CIP1 and GADD45, respond to DNA damage in human and mouse cells, particularly focusing on their behavior in relation to a protein called p53. The researchers found that after exposure to radiation, both genes quickly increased their activity in cells that have p53, and when used together, they were more effective at stopping cell growth than either one alone. This is important because it helps us understand how cells respond to DNA damage and could lead to better strategies for treating conditions like cancer where DNA repair is crucial.
Who this helps: This research benefits patients with cancer and doctors developing targeted treatments.
Flow cytometric identification of intracellular antigens: detection of minimal residual leukemia.
1990
Bone marrow transplantation
Gore S, Kastan M, Civin C
Plain English This study looked at a new way to find small amounts of leukemia that might still be in a patient’s body after treatment. Researchers used a method called two-color flow cytometry, which can identify specific cells by their markers. They found that they could detect T-cell acute lymphoblastic leukemia in remission bone marrow samples with a sensitivity of 0.03%, meaning they can spot very tiny traces of the disease that might otherwise go unnoticed.
Who this helps: This benefits doctors and researchers focused on leukemia treatment and monitoring.